Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short term Debt: 2022-2023

Historic Short term Debt for C4 Therapeutics (CCCC) over the last 1 years, with Jun 2023 value amounting to $10.3 million.

  • C4 Therapeutics' Short term Debt rose 1278.00% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year increase of 1278.00%. This contributed to the annual value of $2.3 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q2 2023, C4 Therapeutics' Short term Debt is $10.3 million, which was up 351.90% from $2.3 million recorded in Q1 2023.
  • Over the past 5 years, C4 Therapeutics' Short term Debt peaked at $10.3 million during Q2 2023, and registered a low of $750,000 during Q1 2022.
  • Moreover, its 2-year median value for Short term Debt was $2.3 million (2022), whereas its average is $3.1 million.
  • Data for C4 Therapeutics' Short term Debt shows a peak YoY skyrocketed of 1,278.00% (in 2023) over the last 5 years.
  • C4 Therapeutics' Short term Debt (Quarterly) stood at $2.3 million in 2022, then soared by 1,278.00% to $10.3 million in 2023.
  • Its Short term Debt was $10.3 million in Q2 2023, compared to $2.3 million in Q1 2023 and $2.3 million in Q4 2022.